|
||||
| HOME | ABOUT US | PIPELINE | R & D | PUBLICATIONS | PARTNERING | INVESTORS | CAREERS | CONTACT | ||||
|
Neurological Diseases - Alzheimer’s Disease - Epilepsy - Depression Cancer Strategic Collaborators Resources |
|
|||
|
The SIGMACEPTOR™-N Program Anavex’s preclinical data has verified the anti-amnesic and neuroprotective action of sigma-1 receptor ligands in various in vitro systems and validated animal models. In our SIGMACEPTOR™-N program, Anavex is taking advantage of these properties to develop new drug candidates for Alzheimer’s Disease, epilepsy, depression and stroke. We have a strong portfolio of compounds targeting several Central Nervous System diseases. Leading marketed therapies in Alzheimer’s Disease work partially through a sigma-1 receptor mechanism. |
||||
| © 2007-2011 Anavex Life Sciences Corp. - All Rights Reserved. | ||||